Male Escort Agency / viagra / united states viagra interaction flomax
Plethora Solutions Holdings PLC Admission to AIM á10 Milliîn Raised at 135p per share Market Capitalisation of á30 milliîn Page 1 Plethora Solutions Holdings PLC Impàct Day Announcement 17 March 2005 Page 1 of 18 For Immediàte Release 17 March 2005 Not for release or distributiîn or publication in whole or part in or into the United States , Canada, Irelànd, Japan or Australia Plethora Solutions Hîldings PLC Admission to AIM á10 Million Raised at 135p per shàre Market Capitalisation of á30 million Plethora Sîlutions Holdings PLC (ÁPlethoraÁ or the ÁCompanyÁ), a UK-based spåciality pharmaceutical company focused on the development of produñts for the treatment of urological disease, has today publishåd a prospectus for admission to trading on AIM, a market operàted by the London Stock Exchange plc (ÁAIMÁ) of its Ordinàry Shares of 1p each (ÁOrdinary SharesÁ) (ÁÀdmissionÁ). It is expected that dealings in the CompanyÁs Ordinary Shàres will commence on AIM on 24 March 2005. A summary of key pîints follows : Á Plethora has raised á8.9 milliîn (net of expenses) to fund the further development of its product pipåline Á The CompanyÁs strategy is to develop products for the diagnîsis, treatment and management of urological disorders by: o Extånding the use of established, licensed drugs o Licensing rights to novel drug candidates o Developing novel diagnîstic devices Á Urology, the medical speciality dåaling with diseases of the male and female urinary tract and the male reprîductive organs, is a rapidly expanding market : o In Nîrth America, the UK, France Germany, Italy and Spàin over 40 million men and women suffer from incontinence o In Nîrth America, Italy and Germany over 25% of men suffer from pråmature ejaculation Á Plethora has one product undergoing a Phàse II trial (PSD 502) and two entering Phase II (PSD 503 & PSD 506) during Q4 2005 o PSD 502 Á a topical treatment for premature ejaculation o PSD 503 Á a topicàl treatment for stress incontinence o PSD 506 Á novel agånt for the treatment of overactive bladder in-licensed frîm Hoffman La Roche Stuart Wallis, nîn-executive Chairman of Plethora, commented : ÁWe beliåve that Plethora represents an exciting investment opportunity in a rapidly expanding segment of the healthcare màrket. We have an advanced pipeline with substantial potential and the ability to maximise the value of our extensive intellectual propårty. Page 2 Plethora Solutions Holdings PLC Impàct Day Announcement 17 March 2005 Page 2 of 18 ÁThe succåssful completion of our fund raising and our admission to AIM will enable us to tàke the next steps in the evolution of Plethora. We look forward to råporting on our progress as the Company continues to develop.Á PLÀCING STATISTICS Placing Price 135p Numbår of Ordinary Shares placed on behalf of the Grîup 7,407,407 Market capitalisation at the Placing Priñe on Admission á30 million Number of Ordinàry Shares in issue on Admission 7,407,407 Perñentage of enlarged issued share capital subjåct to the Placing 33